Alnylam Pharmaceuticals revenue and financials
$223.94Change from previous close: +1.84%Absolute change: +$4.05
In the fiscal year ended December 2025, Alnylam Pharmaceuticals reported revenue of $3.71B (+65.19% year over year). Net income was $313.75M, a net margin of 8.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +65.19%
- 2025 vs 2024
- Net margin
- 8.4%
- 2024: -12.4%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 3,714 | 2,248 | 1,828 | 1,037 | 844 | 493 | 220 | 74.9 | 2.9 | 89.9 |
| Cost of revenue | 677 | 307 | 268 | 140 | 115 | 74.2 | 25.1 | 1.8 | — | 0.0 |
| Gross profit | 3,032 | 1,925 | 1,518 | 869 | 704 | — | — | — | — | — |
| Selling, general and administrative | 1,211 | 976 | 796 | 771 | 621 | — | — | — | — | — |
| Research and development | 1,320 | 1,126 | 1,004 | 883 | 792 | 655 | 655 | 505 | — | 391 |
| Operating income | 502 | -177 | -282 | -785 | -709 | -828 | -939 | -815 | — | -500 |
| EBIT | 502 | -177 | -282 | -785 | -709 | — | — | — | — | — |
| EBITDA | 557 | -120 | -228 | -741 | -661 | — | — | — | — | — |
| Interest expense | 253 | 142 | 121 | 156 | 143 | 84.5 | 0.0 | 0.0 | — | — |
| Pre-tax income | 323 | -377 | -434 | -1,127 | -852 | — | — | — | — | — |
| Income tax | 9.4 | -99.2 | 6.7 | 4.2 | 0.7 | 2.7 | 0.9 | 0.8 | — | 0.0 |
| Net income | 314 | -278 | -440 | -1,131 | -853 | -858 | -886 | -761 | — | -491 |
| Net income to common shareholders | 314 | -278 | -440 | -1,131 | -853 | — | — | — | — | — |
| Basic EPS | 2.39 | -2.18 | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | — | — | — |
| Diluted EPS | 2.33 | -2.18 | -3.52 | -9.30 | -7.20 | -7.46 | -8.11 | — | — | — |
| Average shares (basic) | 131 | 128 | 125 | 122 | 118 | — | — | — | — | — |
| Average shares (diluted) | 135 | 128 | 125 | 122 | 118 | 115 | 109 | — | — | — |